Cancer Community

Cancer InformationYour Pathway to Patient Centered Information

Micro-RNA control the effect Oxaliplatin has on Colorectal Cancer

oxaliplatin-injectionsScientists in Denmark have discovered a Micro-RNA that can foresee the effect Oxalipatin will have on a patient wit Colorectal Cancer. This discovery could allow for improving currently available treatments and could aid in creating new treatments.

There are multiple regiments of chemotherapy that are prescribed to combat colorectal cancer, but for an as yet unknown reason (or reasons) 50 percent of individuals don’t act in response to 1st line treatments. This complicates the selection of a treatment option, but when coupled with the possibility that the body might resist the treatment chosen is troublesome.
With 50 percent unresponsive and no way to predict if the body will resist, many individuals are subjected to treatment regimens that are ineffective but still have all the nasty side effects associated with said treatments. Many times various treatment need to be tried until the one that is right for that particular “patient” is found.

Those very reasons are exactly why so much excitement has been generated around the Danish scientist having made the discovery of the micro-RNA which is called MIR-625-3P, and this molecules direct effect on Oxaliplatin, which is a platinum based antineoplastic chemotherapy agent commonly called Eloxatin. This new molecule MIR-625-3P could very possibly be sued as a bio-marker that could foresee the possibility of a patient being resistant to treatment.

In the study scientists discovered risk of resistance at levels six times that in individuals with tumors that portrayed the MIR-625-3P molecule. Additionally the research concluded there was a direct link showing that the MIR-625-3P molecule inhibited a response to Oxaplatin, the proof being that by removing MIR-625-3P from the tumor and treatment equation, the typically predicted reactions to Oxaplatin began to occur. In short; once MIR-625-3P was gone, the Oxaplatin could do its job.

Applying this research directly to patients, doctors can screen and select what individuals will respond to Oxaplatin and which individuals will not and therefore need an alternate regiment. Patients could avoid the aforementioned “trial and error” application of treatments in the attempt to find the correct one.

Leave a Reply

Your email address will not be published. Required fields are marked *